Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status

Medicine and Dentistry

• COVID-19 100%
• Therapeutic Procedure 22%
• Coronavirinae 22%
• Diseases 16%
• Chloroquine 11%
• Drug 11%
• Chemotherapeutic Agent 11%
• Hydroxychloroquine 11%
• Severe Acute Respiratory Syndrome Coronavirus 2 11%
• Clinical Trial 11%
• Drug Therapy 5%
• Exercise 5%
• Vaccine 5%
• Quarantine 5%
• Arthritis 5%
• Influenza 5%
• Antivirus Agent 5%
• Malaria 5%
• Symptom 5%
• Common Cold 5%
• SARS Coronavirus 5%
• Laboratory 5%
• Health 5%
• Clotiazepam 5%
• Incidence 5%
• Patient 5%
• Medication 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Coronavirinae 22%
• Diseases 16%
• Virus 16%
• Drug 11%
• Chloroquine 11%
• Hydroxychloroquine 11%
• Human 5%
• Influenza 5%
• Antivirus Agent 5%
• Vaccine 5%
• Severe Acute Respiratory Syndrome 5%
• SARS Coronavirus 5%
• Malaria 5%
• Rheumatoid Arthritis 5%
• Pandemic 5%
• Middle East Respiratory Syndrome 5%
• Common Cold 5%
• Clotiazepam 5%
• Incidence 5%
• Death 5%
• Symptom 5%
• Drug Development 5%

Immunology and Microbiology

• Coronavirinae 22%
• Virus 16%
• Chloroquine 11%
• Hydroxychloroquine 11%
• Vaccine Efficacy 5%
• Human 5%
• Influenza 5%
• Malaria 5%
• Exercise 5%
• SARS Coronavirus 5%
• Development 5%
• Health 5%
• Incidence 5%
• Severe Acute Respiratory Syndrome 5%
• Middle East Respiratory Syndrome 5%